5-Aminovaleric acid hydrochloride
(Synonyms: 5-氨基戊酸) 目录号 : GC12713
5-氨基戊酸盐酸盐被认为是 γ-氨基丁酸 (GABA) 的亚甲基同系物，并作为弱 GABA 激动剂发挥作用。
Cas No.:660-88-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
5-Aminovaleric acid has been identified as an important five-carbon platform chemical, which can be used for the synthesis of polymers and other chemicals of industrial interest as well.
In vitro: 5-Aminovaleric acid, a GABA analog, was reported to be able to inhibit GABA uptake, inactivate GABA aminotransferase, and could also both agonize and antagonize GABAb receptors. In addition, 5-aminovaleric acid has been found to be able to increase glutamine concentrations, thus possibly compensating for the decreased concentration of brain glutamine [1].
In vivo: Animal study found that 5-aminovaleric acid-treated rats showed a 3.5-fold reduction in the number of seizures than PBS-treated rats. In addition, both groups showed similar seizure frequency (~1 seizure/day). However, the fraction of the most severe type of seizures increased over time in the PBS treated group, but not in the 5-aminovaleric acid treated group. Moreover, 5-aminovaleric acid treated rats experienced a 2.3- and 2.6-fold lower fraction of stage 4 and 5 seizures than PBS-treated rats [1].
Clinical trial: Aminocaproic acid has been approved by FDA for the treatment of acute bleeding caused by elevated fibrinolytic activity. It has also been used for the prevention of recurrent hemorrhage in patients with traumatic hyphema [https://en.wikipedia.org/wiki/Aminocaproic_acid].
Reference:
[1] Dhaher R,Damisah EC,Wang H,Gruenbaum SE,Ong C,Zaveri HP,Gruenbaum BF,Eid T. 5-aminovaleric acid suppresses the development of severe seizures in the methionine sulfoximine model of mesial temporal lobe epilepsy. Neurobiol Dis.2014 Jul;67:18-23.
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 8.5361 mL | 42.6803 mL | 85.3606 mL |
| 5 mM | 1.7072 mL | 8.5361 mL | 17.0721 mL |
| 10 mM | 0.8536 mL | 4.268 mL | 8.5361 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。